Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.34 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31677750 | 0.93 | MAPK11 (0.37) | MAPTHPGDMAPK14MAPK11FGFR4 | |
| SCHEMBL31677829 | 0.91 | MAPK14 (0.37) | MAPK14CYP3A4NPC1 | |
| SCHEMBL31677638 | 0.90 | KDR (0.36) | MAPTMAPK14MAPK11 | |
| SCHEMBL31677862 | 0.89 | EZH2 (0.37) | MAPTMAPK14MAPK11 | |
| SCHEMBL31677699 | 0.85 | CRHR1 (0.39) | MAPK14MAPK11 | |
| SCHEMBL31677651 | 0.85 | NAMPT (0.36) | MAPT | |
| SCHEMBL31677853 | 0.84 | KDM4E (0.42) | MAPTHPGDKMT2AMEN1 | |
| SCHEMBL31677697 | 0.83 | TGM2 (0.35) | MAPT | |
| SCHEMBL31677679 | 0.82 | BTK (0.37) | MAPT | |
| SCHEMBL31677716 | 0.82 | MAPT (0.34) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270217-A1 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2025-08-28 | — | — | US | claimed |
| US-20250270217-A1 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2025-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270217-A1 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES HAVING A COVALENT WARHEAD AT THE 3-POSITION AS WRN INHIBITORS | WRN, RECQL, BLM | MAPT 4647/4885HPGD 861/4885F10 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.